Abstract Neuroinflammation and blood–brain barrier (BBB) dysfunction are key contributors to the pathogenesis of many neurological disorders. Cannabinoid receptor 2 (CB2) agonists possess anti-inflammatory properties and may represent promising therapeutic agents for preserving BBB integrity. This study evaluated the effects of orally bioavailable CB2 receptor agonists on leukocyte–endothelial interactions and BBB function using in vitro and in vivo models of neuroinflammation.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Sachin
Contact Sachin, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack